Study on the Safety and Tolerability of Postoperative Radiotherapy Concurrent With CDK4/6 Inhibitors in HR+/HER2- High-Risk Breast Cancer

NCT07446686 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: CDK4/6 inhibitor±endocrine therapy drug±OFS treatment combined with synchronous radiotherapy

Sponsor

Guizhou Provincial People's Hospital